Assertio Holdings, Inc. is a commercial pharmaceutical company, which engages in acquisitions, licensing, and mergers. The company is headquartered in Lake Forest, Illinois and currently employs 58 full-time employees. The firm has built its commercial portfolio through the acquisition or licensing of approved products. Its commercial capabilities include marketing through both a sales force and an omni-channel promotion model, market access through payor contracting, and trade and distribution. The Company’s primary marketed products include ROLVEDONTM (eflapegrastim-xnst) injection for subcutaneous use, INDOCIN (indomethacin) Suppositories, INDOCIN (indomethacin) Oral Suspension, Sympazan (clobazam) oral film, Otrexup (methotrexate) injection for subcutaneous use, SPRIX (ketorolac tromethamine) Nasal Spray, and CAMBIA (diclofenac potassium for oral solution). INDOCIN (indomethacin) Suppositories and INDOCIN (indomethacin) Oral Suspension products are nonsteroidal anti-inflammatory drugs (NSAID). Otrexup is a once weekly single-dose auto-injector containing methotrexate.
Chiffres en millions de dollars américains. L'exercice financier va de février à janvier.
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Revenus
137
124
152
156
111
106
Croissance des revenus (H/H)
10%
-18%
-3%
41%
5%
-54%
Coût des ventes
44
39
27
17
15
15
Bénéfice brut
93
85
125
138
95
90
Vente, Général et Administration
76
74
77
46
56
105
Recherche et développement
2
3
2
--
0
4
Frais d'exploitation
110
104
109
79
84
134
Autres revenus (charges) non opérationnels
2
2
2
0
0
-3
Bénéfice avant impôts
-29
-21
-254
31
0
-45
Charge d'impôt sur le revenu
0
0
77
-78
0
-17
Bénéfice net
-28
-21
-331
109
-1
-28
Croissance du bénéfice net
-59%
-94%
-404%
-11,000%
-96%
-87%
Actions en circulation (diluées)
7.1
6.35
4.73
3.64
2.87
1.74
Variation des actions (H-H)
12%
34%
30%
27%
65%
48%
EPS (dilué)
-4
-3.39
-70.09
30.07
-0.45
-16.08
Croissance du EPS
-63%
-95%
-333%
-6,781.99%
-97%
-91%
Flux de trésorerie libre
12
26
48
63
5
-65
Flux de trésorerie libre par action
--
--
--
--
--
--
Marge brute
67.88%
68.54%
82.23%
88.46%
85.58%
84.9%
Marge opérationnelle
-11.67%
-14.51%
10.52%
37.17%
9.9%
-40.56%
Marge bénéficiaire
-20.43%
-16.93%
-217.76%
69.87%
-0.9%
-26.41%
Marge du flux de trésorerie libre
8.75%
20.96%
31.57%
40.38%
4.5%
-61.32%
EBITDA
15
7
44
91
39
-19
Marge EBITDA
10.94%
5.64%
28.94%
58.33%
35.13%
-17.92%
D&A pour le résultat opérationnel
31
25
28
33
28
24
EBIT
-16
-18
16
58
11
-43
Marge EBIT
-11.67%
-14.51%
10.52%
37.17%
9.9%
-40.56%
Taux d'imposition effectif
0%
0%
-30.31%
-251.61%
0%
37.77%
Follow-Up Questions
Assertio Holdings Inc'in temel mali tabloları nelerdir?
Son mali tabloya (Form-10K) göre, Assertio Holdings Inc'in toplam varlıkları $284 olup, net perte $-21'dir.
ASRT'ün temel finansal oranları nelerdir?
Assertio Holdings Inc'in cari oranı 1.74, net kâr marjı -16.93, hisse başına satış $19.52'dir.
Assertio Holdings Inc'in geliri segment veya coğrafya bazında nasıl dağılıyor?
Le segment de revenus le plus important est Assertio Holdings Inc, avec un chiffre d'affaires de Pharmaceutical lors du dernier rapport de résultats. En termes géographiques, United States est le marché principal pour Assertio Holdings Inc, avec un chiffre d'affaires de 124,961,000.
Assertio Holdings Inc kârlı mı?
non, son mali tablolara göre Assertio Holdings Inc'in net perte $-21'dir.
Assertio Holdings Inc'in herhangi bir yükümlülüğü var mı?